Mechanisms of action of low-dose IL-2 restoration therapies in SLE

被引：26
|
作者：
Ballesteros-Tato, Andre [1 ]
Papillion, Amber [1 ]
机构：
[1] Univ Alabama Birmingham, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA
来源：
CURRENT OPINION IN IMMUNOLOGY | 2019年 / 61卷
基金：
美国国家卫生研究院;
关键词：
REGULATORY T-CELLS; FOLLICULAR HELPER-CELLS; INTERLEUKIN-2; PRODUCTION; SELECTIVE STIMULATION; MICE; AUTOIMMUNE; DEFICIENCY; RESPONSES; RECEPTOR; SUBSETS;
D O I：
10.1016/j.coi.2019.07.003
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Interleukin-2 (IL-2) shortage is a hallmark of Systemic Lupus Erythematosus (SLE). Importantly, clinical and preclinical studies demonstrate the potential clinical benefits of IL-2 based restoration therapies for the treatment of SLE. Here we discuss the immunological consequences of IL-2 deficiency in SLE patients and the mechanisms underlying the therapeutic effects of low-dose IL-2 regimens.
引用
收藏
页码：39 / 45
页数：7
相关论文
共 50 条
  • [1] Low-dose IL-2 for SLE
    Thorley, Jennifer
    LANCET RHEUMATOLOGY, 2019, 1 (03): : E143 - E143
  • [2] Emerging mechanisms and applications of low-dose IL-2 therapy in autoimmunity
    Zhou, Pengcheng
    CYTOKINE & GROWTH FACTOR REVIEWS, 2022, 67 : 80 - 88
  • [3] Low-Dose IL-2 in the Treatment of Lupus
    Masayuki Mizui
    George C. Tsokos
    Current Rheumatology Reports, 2016, 18
  • [4] Low-Dose IL-2 in the Treatment of Lupus
    Mizui, Masayuki
    Tsokos, George C.
    CURRENT RHEUMATOLOGY REPORTS, 2016, 18 (11)
  • [5] Local low-dose IL-2 therapy
    Den Otter, W
    Balemans, L
    Battermann, JJ
    Bernsen, MR
    Cadee, JA
    Dobrowolski, Z
    Everse, LA
    Fiszer-Maliszewska, L
    Gavhumende, R
    De Groot, JW
    De Groot, K
    Hennink, WE
    Hill, FWG
    Jurgenliemp-Schulz, I
    Klein, WR
    Koten, JW
    Maas, RA
    Steerenberg, P
    Stewart, R
    Zembala, M
    HEPATO-GASTROENTEROLOGY, 1999, 46 : 1280 - 1286
  • [6] EFFICACY OF LOW-DOSE IL-2 IN PATIENTS WITH MYOSITIS
    Wang, X. M.
    Zhang, J. X.
    Chai, P. H.
    Li, Y. Z.
    Su, Q. Y.
    Yu, Q.
    He, P. F.
    Li, X.
    Zhang, S. X.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1671 - 1672
  • [7] Low-dose IL-2 therapy for autoimmune diseases
    Collison J.
    Nature Reviews Rheumatology, 2019, 15 (1) : 2 - 2
  • [8] Low-dose IL-2 mitigates glucocorticoid-induced Treg impairment and promotes improvement of SLE
    Haotian Zhou
    Xiaozhen Zhao
    Ruijun Zhang
    Miao Miao
    Wenwen Pei
    Zijun Li
    Yimin Li
    Jing He
    Zhanguo Li
    Xiaolin Sun
    Signal Transduction and Targeted Therapy, 8
  • [9] Low-dose IL-2 mitigates glucocorticoid-induced Treg impairment and promotes improvement of SLE
    Zhou, Haotian
    Zhao, Xiaozhen
    Zhang, Ruijun
    Miao, Miao
    Pei, Wenwen
    Li, Zijun
    Li, Yimin
    He, Jing
    Li, Zhanguo
    Sun, Xiaolin
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2023, 8 (01)
  • [10] LOW-DOSE IL-2 THERAPY IN SLE: RESULTS FROM A COMBINED PHASE I/IIA CLINICAL TRIAL
    Humrich, J.
    Von Spee-Mayer, C.
    Siegert, E.
    Bertolo, M.
    Rose, A.
    Abdirama, D.
    Enghard, P.
    Hiepe, F.
    Radbruch, A.
    Burmester, G. -R.
    Riemekasten, G.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (04) : S13 - S13
12345